Excess deaths during the COVID-19 pandemic in Alberta, Canada

Sanjay Beesoon\textsuperscript{a,7}, Jeffrey A. Bakal\textsuperscript{b,c,d,7,8}, Erik Youngson\textsuperscript{b,c}, Kienan P. Williams\textsuperscript{e}, Sandra A. Berzins\textsuperscript{a,f,8}, Mary E. Brindle\textsuperscript{a,8}, A. Mark Joffe\textsuperscript{d,h}

\textsuperscript{a} Surgical Strategic Clinical Network, Alberta Health Services, Edmonton, Alberta, Canada
\textsuperscript{b} Provincial Research Data Services, Alberta Health Services, Edmonton, Alberta, Canada
\textsuperscript{c} Data and Research Services, Alberta SPOR SUPPORT Unit, Edmonton, Alberta, Canada
\textsuperscript{d} Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
\textsuperscript{e} Indigenous Wellness Core, Alberta Health Services, Edmonton, Alberta, Canada
\textsuperscript{f} Departments of Psychiatry and Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
\textsuperscript{g} Matthew Centre for Mental Health Education and Research, University of Calgary, Calgary, Alberta, Canada
\textsuperscript{h} Cancer Care Alberta, Clinical Support Services and Provincial Clinical Excellence, Alberta Health Services, Edmonton, Alberta, Canada

\textbf{A B S T R A C T}

Objectives: To determine if there was excess mortality in Alberta, Canada during the coronavirus disease 2019 (COVID-19) pandemic, to confirm if excess mortality affected all age groups equally, and to determine what proportions of excess deaths were directly related to COVID-19 and non-pharmaceutical drug poisoning.

\textbf{Methods}: Weekly all-cause data used to estimate excess mortality were modelled against the pre-pandemic period (January 2015–February 2020). Age-adjusted weekly mortality rates for March 2020 to December 2021 were compared with the preceding 5 years.

\textbf{Results}: From March 2020 to December 2021, there was an 11% excess mortality rate, corresponding to an average of 265 monthly excess deaths (maximum >30%). COVID-19-related deaths (n=3202) accounted for 54.9% of total excess deaths (n=5833) that occurred in the 22-month period. The increase in all-cause excess deaths was proportionately higher, and with significantly greater numbers, in younger age groups. Significant increases in monthly drug poisoning deaths occurred from March 2020 to April 2021, with a total of 1819 deaths. Eight hundred and twenty-five drug poisoning deaths, representing 25.4% of total all-cause excess deaths, occurred, mainly among those aged 25–60 years. Overall, 54.9% of all excess deaths were directly related to COVID-19 and 25.4% were related to drug poisoning.

\textbf{Conclusions}: There was a significant increase in all-cause mortality during the COVID-19 pandemic. Although older adults are more likely to die of COVID-19, a massive increase in non-COVID-19-related mortality was observed among younger people. These factors should be considered in public policy decisions on epidemic/pandemic management.

\textbf{Introduction}

Following the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019, with high case fatality rates reported in China (3.8–14.6% from 1 to 17 January 2020), the international public health community reacted promptly by implementing a suite of major non-pharmaceutical interventions (Mi et al., 2020). In the Western world, these measures were initially accepted as necessary, but scepticism emerged over time (Melnick and Ioannidis, 2020) and some questioned whether drastic measures that led to economic losses, adverse mental health outcomes and infringement on personal liberties were proportional to disease severity (Bowcott, 2020). In some jurisdictions, health services, such as elective surgeries, were deferred to prepare the health system to manage potential surges in hospitalizations and intensive care unit (ICU) admissions (CHI, 2020). Fear of coronavirus disease 2019 (COVID-19) deterred some patients from accessing vital medical services. For example, more than 40% of American adults chose not to access medical care due to concerns about the risk of contracting COVID-19 in healthcare settings (Czeisler et al., 2020). The same effect has been found in the Canadian health system, including Alberta, where overall emergency department visits decreased by 35% (incidence rate ratio (IRR) 0.65, P<0.001), and surgical and medical admissions through emergency departments decreased by 18% (IRR 0.82, P<0.001) and 14% (IRR 0.86, P<0.001), respectively (Rennert-May et al., 2021).

Although policy makers are subjected to a daily onslaught of massive amounts of data and advice from scientists, modellers, economists, disaster management professionals and legal experts, public health decision making usually relies on case numbers, test positivity rates, clinical severity of disease, hospital admissions and case fatality rates. Comparing absolute numbers of deaths or mortality rates across different jurisdictions can be problematic as the numbers can be biased due to differences in case definitions, SARS-CoV-2 testing criteria, and reporting of deaths as being ‘due’ to COVID-19 as opposed to...
‘with’ COVID-19. To assess the real impact of the COVID-19 pandemic, all-cause mortality, which compares mortality over a given period with the historical baseline, is emerging as a reliable, objective and gold standard metric (Simonsen and Viboud, 2021; Weinberger et al., 2021; Lee et al., 2022; McGrail, 2022). With the exception of a few countries, such as Australia, Singapore, Iceland and Norway, excess mortality was documented in most jurisdictions impacted by the COVID-19 pandemic (COVID-19 Excess Mortality Collaborators, 2022). Although it was initially unclear whether the excess mortality rate was solely attributable to COVID-19, recent reports are confirming major mortality impacts during the pandemic. For example, based on US data collected from August 2014 to April 2021, Lee et al. (2022) reported higher excess mortality for diabetes, heart disease, Alzheimer’s disease, cerebrovascular disease, accidents and injuries, drug overdoses, and assaults and homicides during the pandemic. Likewise, DiGennaro et al. (2021) found significant excess drug overdose mortality during the pandemic. In Canada, deaths due to opioid poisoning increased significantly during the pandemic. Increased toxicity of non-pharmaceutical drugs in Alberta, particularly fentanyl, contributed to the increased number of accidental drug poisoning deaths in 2021 (Public Health Agency of Canada, 2022).

This study aimed to confirm whether the COVID-19 pandemic was accompanied by excess all-cause mortality in Alberta, Canada, to determine which age groups were most impacted, and to tease out subtle factors driving the mortality trends.

Methods

Mortality data were obtained from the Alberta Vital Statistics database, accessed through Alberta Health Services, Data and Analytics. The Vital Statistics database tracks all births and deaths in the province of Alberta, and is maintained by Service Alberta. Population estimates were obtained from the Alberta Population Health Statistics database, which contains estimates for the population of Alberta stratified by various attributes including sex, age and postal code, and is derived from the Provincial Registry which tracks registration with the Alberta Health Care Insurance Plan. Deaths related to COVID-19 were obtained from the Communicable Disease Outbreak Management system, which is used for contact tracing and follow-up of people with confirmed COVID-19. Deaths were considered to be related to COVID-19 if the cause of death was recorded as being ‘from the disease’ or the disease ‘contributed to the death (secondary cause)’. In addition, publicly available data from Alberta’s substance use surveillance system (Alberta Health-A, 2022) were used to look at the number of deaths associated with substance abuse by age and sex in the same time frame.

All-cause deaths were summarized weekly between 2015 and 2021, and stratified by pre-specified 10-year age groups. Weekly data were used to estimate excess mortality using an overdispersed Poisson model, where expected mortality was based on the pre-pandemic period (January 2015–February 2020). Total cumulative excess mortality between March 2020 and December 2021 was estimated, as well as the proportion of the increase relative to expected mortality, overall and for each age group. All statistical analyses were conducted using SAS Version 9.4 (Cary, NC, USA) and R Version 4.1.2 (Vienna, Austria), including the excessmort package for estimation of excess mortality (Acosta and Irizarry, 2022).

Results

The province of Alberta has a population of approximately 4.4 million people, and an observed COVID-19 case rate of 8411 per 100,000 people in Alberta from 15 March 2020 to 31 December 2021 (Alberta Health-B, 2022). As can be seen in Figure 1, significant excess deaths were observed compared with expected deaths for the 22-month period from March 2020 to December 2021. In Alberta, the first COVID-19-associated fatality was reported in early March 2020. From March 2020 to December 2021, the estimated total excess deaths was 5833 (95% confidence interval (CI) 5373–6293), which equates to an average of approximately 265 excess deaths per month. The highest excess mortality relative to the expected death rate occurred in late 2020 and late 2021, with maximum weekly increases of 33.1% (95% CI 27.4–28.8%) for the week ending 24 September 2021 and 30.4% (95% CI 25.6–35.3%) for the week ending 25 December 2020 (Figure 2). There were only three periods where a significant increase in excess mortality was not observed: (i) prior to the week ending 20 March 2020; (ii) between the weeks ending 8 May 2020 and 10 July 2020; and (iii) between the weeks ending 12 February 2021 and 9 April 2021 (Figure 2). COVID-19-related deaths (n=3202) accounted for 5.7% of all deaths since March 2020 (n=56,010), but 54.9% of the total excess deaths (n=5833) that occurred over the 22-month period. There was strong correlation between the weekly estimated excess deaths and COVID-19-related deaths (Pearson correlation, r=0.75).

The analysis of weekly data stratified by age group suggests that there was no significant excess mortality in the 0–9-years age group and generally very little excess mortality in the younger age groups. The older age groups followed the pattern observed in the overall population, with peaks in late 2020 and late 2021; however, the 30–39-years age group showed steady increasing excess mortality throughout the pandemic (Figure 3). Alberta data show that most COVID-19 deaths were in the older age groups, notably in those aged >80 years.

Based on Alberta substance use surveillance system data (Alberta Health-A, 2022), there was an increase in the number of deaths associated with non-pharmaceutical drug poisoning. The surveillance group found that totals of 1579 and 1818 deaths in 2020 and 2021, respectively, were attributed to drug poisoning related to any substance (opioids, methamphetamine, cocaine, alcohol, benzodiazepines or other). These numbers correspond to an excess of 534 and 946 drug poisoning deaths in 2020 and 2021, respectively, compared with the mean of 825 drug poisoning deaths in each of the four preceding years. The 1480 excess drug poisoning deaths account for 59% of the 2514 non-COVID-19 imputed excess deaths and 25.4% of the total all-cause excess deaths between March 2020 and December 2021, and occurred primarily in those aged 25–60 years. Of the 1545 non-pharmaceutical opioid drug poisoning deaths in 2021, the highest proportion of deaths occurred in young men aged 25–44 years (41.4%, n=639) (Alberta Health-A, 2022). Overall, 80.3% of all-cause excess mortality can be accounted for by COVID-19-related deaths (54.9%) and drug poisoning deaths (25.4%) (Figure 4). The remaining 19.7% of excess deaths are likely due to a constellation of factors including, but not limited to, delay in accessing urgent and critical medical care, suboptimal chronic disease follow-up, and potential adverse outcomes associated with delay in some surgeries.

Discussion

Despite both the death rate (75/100,000) and the overall case fatality rate (0.8%) being lower in Alberta than in more heavily populated Canadian provinces such as Ontario and Quebec, all-cause excess mortality was higher in Alberta (McGrail, 2022). The present study confirmed that the COVID-19 pandemic was associated with excess mortality in Alberta, and permits deeper exploration of possible reasons. Importantly, nearly half of the excess deaths in the study period did not appear to be COVID-19-related. Given the robust infectious disease surveillance infrastructure in Alberta, it is unlikely that the 43.1% of excess deaths attributed to non-COVID-19 causes were exclusively due to under-reporting, although it is possible that some COVID-19 deaths may have been attributed to other underlying co-morbidities.

In recent months, several papers have been published documenting potential associations between non-COVID-19 imputed excess mortality and diabetes, Alzheimer’s disease, cerebrovascular disease (Glei, 2022) and heart disease (Brant et al., 2020), which are possibly due to avoidance or inaccessibility of health care (Czeisler et al., 2020). Furthermore, recent data have shown an increase in homicides (Kegler et al., 2022), suicides (Kaggwa et al., 2022; Orellana and de Souza, 2022; Rogalska...
Figure 1. Cumulative number of coronavirus-disease-2019-related deaths and total excess deaths from March 2020 to December 2021.

Figure 2. Excess mortality across all ages from March 2020 to December 2021.

and Syrkiewicz-Świtła, 2022) and drug poisoning deaths (Faust et al., 2021; Mason et al., 2021; Hawkins and Phan, 2022; Schleinhauf and Bowes, 2022) in other jurisdictions during the pandemic. Alberta has a robust surveillance system for drug poisoning deaths (Alberta Health Services-A, 2022), which was used to verify an increase in the number of drug poisoning deaths from March 2020 to December 2021 (Figure 4).

Many of this increase can be attributed to increased toxicity of the non-pharmaceutical drug supply, especially in the last 6 months of 2021. For example, the Supervised Consumption Service in Calgary, Alberta reported that the average number of daily client visits decreased significantly as public health measures affected site capacity. In December 2019, there were an average of 210.9 visits per day, compared with 100 in December 2021. The proportion of overdoses per number of times that drugs were consumed increased from 1.22% in December 2019 to 7.95% in 2021, reflecting this increased drug supply toxicity (Alberta Health Services-B, 2022).

There are limitations to what can be surmised from the available data. The overall mortality rates are highly accurate, but monthly and yearly fluctuations can impact any precise estimates of excess deaths. Importantly, discerning between deaths attributable to acute COVID-19 infection and non-COVID-19-related deaths requires that testing is available, broadly applied and accurately reported. This example can be seen clearly in Eastern Europe and Latin America in the first wave of COVID-19, where high rates of excess mortality were observed prior to the widespread availability of testing (Ritchie et al., 2020), resulting in a large gap between COVID-19-attributable deaths and the overall in-
Figure 3. Excess mortality by 10-year age groups.
creased number of deaths observed compared with the number of deaths expected. Access to testing was readily available at no cost and with minimal eligibility restrictions to the individual as part of Alberta’s publicly funded healthcare system. With a testing rate of 111,059 per 100,000 population, Alberta had one of the highest per-capita testing rates in the country (Public Health Agency of Canada, 2021). However, there may well have been differences in testing rates across age/sex strata (Sundaram et al., 2021). Implementation of public health measures to control the spread of COVID-19 may reduce mortality rates below expected levels (and underestimate excess mortality) through reductions of other communicable diseases (e.g. influenza), work-related accidents and road traffic fatalities, or may increase mortality, for example, due to substance use and mental-health-related deaths (Moriarty et al., 2021). A deeper exploration of cause of death and contributing factors would help to clarify how these factors may contribute to changes in observed mortality. Although standardized definitions were applied throughout, some misclassification of either COVID-19 or non-COVID-19 deaths is still possible. It is unlikely that COVID-related deaths were missed prior to the first recognized case in the province on 5 March 2020 (Kanji et al., 2021).

Conclusion

This cross-sectional study confirmed earlier findings in other jurisdictions that the COVID-19 pandemic led to substantial excess mortality, and highlights the differences in effect across age groups. Relative death rates were disproportionately higher among young Albertans between 20 and 59 years of age, which was not linked directly to confirmed COVID-19. Analysis of official acute drug poisoning death data during the pandemic strongly suggests that the latter made a substantial contribution to total non-COVID-19 deaths during the study period. It is important to understand the contributions and inter-relations of medical, social and economic factors to explain the high number of non-COVID-19-related excess deaths in order to make policy decisions during future pandemics. This work highlights the importance of looking beyond case counts and case fatality rates in understanding the effects of a pandemic in society.

Acknowledgements

The authors wish to thank Zoe Hsu, Provincial Research Data Services at Alberta Health Services and Alberta SPOR Data and Research Services Team for assistance with data extraction and linkage for the study.

Conflict of interest statement

None declared.

Ethical approval

Ethical approval for this study was obtained from the Health Research Ethics Board of the University of Alberta, Canada (Pro00112035).

References

Acosta RJ, Irizarry RA. A flexible statistical framework for estimating excess mortality. Epidemiol 2022;33:346–53.
Alberta Health A. Alberta substance use surveillance system. Acute substance related deaths by age and sex. Alberta Health; 2022. Available at: https://healthanalytics.alberta.ca/SASvisualAnalytics/?reportUri=%2Freports%2FALh6bb695d-14b1-4346-b66e-d401a40f53e6&sectionIndex=0&ssostatus=0&so_guest=true&reportViewOnly=true&reportContextBar=false&amp;mm=111,059&accessed 1 June 2022.
Alberta Health B. COVID-19 Alberta statistics. Alberta Health; 2022. Available at: https://www.alberta.ca/stats/covid-19-alberta-statistics.htm (accessed 1 June 2022).
Alberta Health Services-A. Safeworks. Calgary’s supervised consumption service at the Sheldon M. Chumir Health Centre. Alberta Health Services; 2022. Available at: https://www.albertahealthservices.ca/info/page15433.aspx (accessed 1 June 2022).
Alberta Health Services-B. Safeworks monthly report – December 2021. Supervised consumption services. Alberta Health Services; 2022. Available at: https://www.albertahealthservices.ca/assets/info/amb/IF-amb-sup-con-chumir-2021-12.pdf (accessed 1 June 2022).
Bocwoc O. Covid measures will be seen as ‘monument of collective hysteria and folly’ says ex-judge. The Guardian, 27 October 2020. Available at: https://www.theguardian.com/law/2020/oct/27/covid-measures-will-be-seen-as-monument-of-collective-hysteria-and-folly-says-ex-judge (accessed 7 July 2021).
Branth LCG, Nascimento BR, Teixeira RA, Lopes MACQ, Malta DC, Oliveira GMM, et al. Excess of cardiovascular deaths during the COVID-19 pandemic in Brazilian capital cities. Heart 2020;106:1986–905.
COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 2022;399:1513–16.
Czeisler C, Clarke KE, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or avoidance of medical care because of COVID-19-related concerns – United States, June 2020. MMWR Morb Mortal Wkly Rep 2020;69:1250–7.
DiGennaro C, Garcia G-GP, Stringfield EW, Wakerman J, Jablecki M. Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. Int J Drug Policy 2021;96.
Faust JS, Krumholz HM, Du C, Mayes KD, Lim Z, Gilman C, et al. All-cause excess mortality and COVID-19 related mortality among US adults aged 25–44 years, March–July 2020. JAMA 2021;225:705–7.
Glei DA. The US midlife mortality crisis continues: excess cause-specific mortality during 2020. Am J Epidemiol 2022. doi:10.1093/aje/kwac055.
Hawkins D, Phan AT. Changes in drug poisoning mortality before and after the COVID-19 pandemic by occupation in Massachusetts. Am J Ind Med 2022;65:556–66.
Kaggwa MM, Rukundo GZ, Wakida EK, Maling S, Senurugamu BM, Atim LM, et al. Suicide and suicide attempts among patients attending primary health care facilities in Uganda: a medical records review. Risk Manag Healthc Policy 2022;15:703–11.

Figure 4. Drug poisoning deaths by age group and sex from 2016 to 2021.
Kanji JN, Diggle M, Bulman DE, Hume S, Taylor S, Kelin R, et al. Retrospective testing of respiratory specimens for COVID-19 to assess for earlier SARS-CoV-2 infections in Alberta, Canada. J Anosc Med Microbiol Infect Dis Can 2021;6:10–15.

Kegler SR, Simon TR, Zwald ML, Chen MS, Mercy JA, Jones CM, et al. Vital signs: changes in firearm homicide and suicide rates – United States, 2019–2020. MMWR Morb Mortal Wkly Rep 2022;71:656–63.

Lee W-E, Park SW, Weinberger DM, Olson D, Simonsen L, Grenfell BT, et al. Direct and indirect mortality impacts of the COVID-19 pandemic in the US, March 2020–April 2021. medRxiv 2022. doi:10.1101/2022.02.10.22270721.

Mason M, Arukumar P, Feinglass J. The pandemic stay-at-home order and opioid-involved overdose fatalities. JAMA 2021;325:2495–6.

Melnick ER, Ioannidis JPA. Should governments continue lockdown to slow the spread of COVID-19? Br Med J 2020;369:m1924.

Mi YN, Huang TT, Zhang JX, Qin Q, Gong YX, Liu SY, et al. Estimating the instant case fatality rate of COVID-19 in China. Int J Infect Dis 2020;97:1–6.

Mortarty T, Boccola AE, Thind MA, McElhaney JE. Excess all-cause mortality during the COVID-19 epidemic in Canada. Royal Society of Canada; 2021.

Orellana JDY, de Souza MLP. Excess suicides in Brazil: Inequalities according to age groups and regions during the COVID-19 pandemic. Int J Soc Psychiatry 2022;68:997–1009. Public Health Agency of Canada. COVID-19 in Canada. Ottawa: PHAC; 2021 Available at https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019-novel-coronavirus-infection/surv-covid19-weekly-epi-update-20210813-en.pdf accessed 1 June 2022.

Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and stimulant-related harms in Canada. Ottawa: Public Health Agency of Canada; 2022.

Rennert-May E, Leal J, Thanh NX, Lang E, Dowling S, Manns B, et al. The impact of COVID-19 on hospital admissions and emergency department visits: a population-based study. PLoS One 2021;16.

Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al. Coronavirus pandemic (COVID-19). 2020. Available at: https://ourworldindata.org/coronavirus (accessed 7 July 2021).

Rogalska A, Syrkiewicz-Świtalska M. COVID-19 and mortality, depression, and suicide in the Polish population. Front Public Health 2022;10.

Schleifarth F, Bowes MJ. Suicide and drug toxicity mortality in the first year of the COVID-19 pandemic: use of medical examiner data for public health in Nova Scotia. Health Promot Chronic Dis Prev Can 2022;42:60–7.

Simonsen L, Viboud C. Mortality: a comprehensive look at the COVID-19 pandemic death toll. Elife 2021;10.

Sundaram ME, Calzavara A, Mishra S, Kundra R, Chan AK, Hamilton MA, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. Can Med Assoc J 2021;193:E723–34.

Weinberger DM, Cohen T, Crawford FW, Mostashari F, Olson D, Pitzer VE, et al. Estimating the early death toll of COVID-19 in the United States. medRxiv 2021. doi:10.1101/2020.04.15.20066431.